The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome.

No abstract is available for this paper.

• Publication year

  1980

• Venue

  Journal of Clinical Endocrinology and Metabolism

• Publication date

  1980-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1210/JCEM-51-2-307PMID 6249835
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tamoxifen enhances the sensitivity of dispersed prolactin-secreting pituitary tumor cells to dopamine and bromocriptine.

  1980cited by this paper
• THE EFFECT OF CYPROHEPTADINE ON THE RELEASE OF CORTICOTROPHIN RELEASING FACTOR

  1979cited by this paper
• Lack of Effect of Antiserotoninergic and/or Dopaminergic Treatment in Patients with Pituitary-Dependent Cushing's Syndrome

  1979cited by this paper
• Plasma cortisol response to thyrotropin-releasing hormone and luteinizing hormone-releasing hormone in Cushing's disease.

  1979cited by this paper
• Studies on the Effect of Cyproheptadine on Growth Hormone Secretion

  1979cited by this paper
• The interaction of the serotonergic and dopaminergic systems on prolactin secretion in the rat. The mechanism of action of the "specific" serotonin receptor antagonist, methysergide.

  1978cited by this paper
• ACTH and cortisol response to bromocriptine, and results of long-term therapy, in Cushing's disease.

  1978cited by this paper
• Lack of effect of bromocriptine on ACTH levels in patients with bilateral adrenalectomy for pituitary-dependent Cushing’s syndrome

  1978cited by this paper
• Effects of cyproheptadine on prolactin synthesis and release by normal and suppressed pituitary glands and by dispersed pituitary tumor cells.

  1978cited by this paper
• Plasma ACTH and cortisol responses to TRF, vasopressin or hypoglycemia in cushing's disease and nelson's syndrome.

  1977cited by this paper
• THE ROLE OF DOPAMINERGIC DEPLETION IN THE PATHOGENESIS OF CUSHING'S DISEASE AND THE POSSIBLE CONSEQUENCES FOR MEDICAL THERAPY

  1977cited by this paper
• Cyproheptadine in Cushing's syndrome.

  1977cited by this paper
• EFFECTS OF GROWTH HORMONE RELEASE‐INHIBITING HORMONE AND BROMOCRYPTINE (CB 154) IN STATES OF ABNORMAL PITUITARY‐ADRENAL FUNCTION

  1976cited by this paper
• Bromocriptine in Nelson's syndrome and Cushing's disease.

  1976cited by this paper
• Effect of bromocriptine in pituitary-dependent Cushing's syndrome.

  1976cited by this paper
• The effect of various putative neurotransmitters on the release of corticotrophin releasing hormone from the hypothalamus of the rat in vitro. I. The effect of acetylcholine and noradrenaline.

  1975cited by this paper
• Inhibition by somatostatin of ACTH secretion in Nelson's syndrome.

  1975cited by this paper
• Relationship of bioassayable and immunoassayable plasma ACTH and cortisol concentrations in normal subjects and in patients with Cushing's disease.

  1975cited by this paper
• Cyproheptadine-induced remission of Cushing's disease.

  1975cited by this paper
• Endocrine profile of a specific prolactin inhibitor: Br-ergocryptine (CB 154). A preliminary report.

  1973cited by this paper
• Determination of dehydroepiandrosterone and dehydroepiandrosterone sulphate in human plasma using electron capture detection of 4-androstene-3,6,17-trione after gas-liquid chromatography.

  1972cited by this paper
• Determination of dehydroepiandrosterone and dehydroepiandrosterone sulphate in human plasma using electron capture detection of 4-androstene-3,6,17-trione after gas-liquid chromatography.

  1972cited by this paper

• Nelson's Syndrome: A Narrative Review

  2023cites this paper
• Management of Nelson’s Syndrome

  2022cites this paper
• The dopaminergic control of Cushing’s syndrome

  2022cites this paper
• Bromocriptine therapy: Review of mechanism of action, safety and tolerability

  2022cites this paper
• Medical management of Cushing's disease

  2021cites this paper
• Cabergoline for Cushing ’ s disease : A case report Cabergolina para la enfermedad de Cushing : a propósito

  2020cites this paper
• Molecular determinants of the response to medical treatment of growth hormone secreting pituitary neuroendocrine tumors.

  2019cites this paper
• Dopamine Agonists for Pituitary Adenomas

  2018cites this paper
• Chapter 2 Molecular Biology of Cushing ’ s Disease

  2017cites this paper
• Chapter 17 – Cushing Disease

  2017cites this paper
• Role of “old” pharmacological agents in the treatment of Cushing’s syndrome

  2016cites this paper
• Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.

  2015cites this paper
• Cabergoline for Cushing's disease: A case report.

  2015cites this paper
• Cushing's Syndrome

  2015cites this paper
• The Treatment of Cushing's Disease.

  2015cites this paper
• Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?

  2014cites this paper
• Medical treatment of Cushing's disease.

  2013cites this paper
• Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics

  2012cites this paper
• Molecular Biology of Cushing’s Disease

  2011cites this paper
• Chapter 9 – The Hypothalamus

  2011cites this paper
• Inhibitory Effect of Prepro‐Thyrotrophin‐Releasing Hormone (178–199) on Adrenocorticotrophic Hormone Secretion by Human Corticotroph Tumours

  2010cites this paper
• Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease

  2010cites this paper
• Cabergoline monotherapy in the long-term treatment of Cushing's disease.

  2010cites this paper
• Pathogenesis of Corticotropic Tumors

  2010cites this paper
• Studies on the PI3K/mTOR pathway as cytostatic treatment target in pituitary adenomas

  2010cites this paper
• Medical Management of Cushing’s Syndrome

  2010cites this paper
• Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome

  2009cites this paper
• The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.

  2009cites this paper
• Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.

  2009cites this paper
• Somatostatin and dopamine receptors as molecular targets for the medical treatment of Cushing’s disease

  2009cites this paper
• Cushing's disease.

  2009cites this paper
• Plasma aldosterone response to metoclopramide in patients with Cushing's disease.

  2009cites this paper
• Six year remission ofACTH-dependent Cushing's syndrome

  2008cites this paper
• Cushing's Syndrome.

  2008cites this paper
• Preclinical and clinical experiences with the role of somatostatin receptors in the treatment of pituitary adenomas

  2007cites this paper
• [Nelson's Syndrome: a case report].

  2007cites this paper
• Dopamine receptor expression and function in corticotroph ectopic tumors.

  2007cites this paper
• caso especial Síndrome de Nelson: Relato de Caso

  2007cites this paper
• Preclinical and clinical experiences with the role of dopamine receptors in the treatment of pituitary adenomas.

  2007cites this paper
• Pharmacological management of Cushing's syndrome: an update.

  2007cites this paper
• Nelson syndrome: comprehensive review of pathophysiology, diagnosis, and management.

  2007cites this paper
• Endocrine clinical update: Where are we in the therapeutic management of pituitary‐dependent hypercortisolism?

  2007cites this paper
• Clinical and biochemical stabilization of Nelson’s syndrome with long-term low-dose cabergoline treatment

  2006cites this paper
• Cushing’s disease

  2006cites this paper
• [Use of cabergoline in persisting Cushing's disease].

  2006cites this paper
• Utilisation de la cabergoline dans la maladie de Cushing non contrôlée

  2005cites this paper
• Cushing’s Syndrome

  2005cites this paper
• The endocrine profile of bromocriptine: Its application in endocrine diseases

  2005cites this paper
• Nelson’s Syndrome: Complete Remission with Cabergoline but Not with Bromocriptine or Cyproheptadine Treatment

  2004cites this paper
• Dopamine receptor expression and function in corticotroph pituitary tumors.

  2004cites this paper
• Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment.

  2004cites this paper
• Papel da terapia medicamentosa na síndrome de Cushing

  2003cites this paper
• The Medical Management of Cushing's Syndrome

  2002cites this paper
• Neurosurgical treatment of Nelson's syndrome.

  2002cites this paper
• Management of Nelson's syndrome: observations in fifteen patients

  2001cites this paper
• WHAT IS THE HEALTH RISK ASSOCIATED WITH AMENORRHEA

  2001cites this paper
• ACTH silent adenoma shrinking under cabergoline.

  2001cites this paper
• Cabergoline

  2000cites this paper
• The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease.

  1999cites this paper
• Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline

  1999cites this paper
• The corticotropin-release inhibitory factor hypothesis: a review of the evidence for the existence of inhibitory as well as stimulatory hypophysiotropic regulation of adrenocorticotropin secretion and biosynthesis.

  1999cites this paper
• Dopamine agonists and analogues have an antiproliferative effect on CHO-K1 cells

  1999cites this paper
• Bromocriptine-induced apoptosis in pituitary adenoma cells: relationship to p53 and bcl-2 expression.

  1999cites this paper
• Absence of dopaminergic control on melanotrophs leads to Cushing's-like syndrome in mice.

  1998cites this paper
• [Pharmacologic treatment of Cushing's syndrome].

  1998cites this paper
• Tratamiento farmacológico del síndrome de Cushing

  1998cites this paper
• Corticotrophin and vasopressin responses to metoclopramide in patients with hypothalamic amenorrhoea

  1997cites this paper
• Management of canine pituitary-dependent hyperadrenocorticism with l-deprenyl (Anipryl).

  1997cites this paper
• Secondary hypertension: evaluation and treatment.

  1996cites this paper
• Canine pituitary-dependent hyperadrenocorticism: a spontaneous animal model for neurodegenerative disorders and their treatment with 1-deprenyl.

  1995cites this paper
• [Comparative characteristics of steroidogenesis and its biorhythm in the hyperfunctioning adrenal cortex].

  1994cites this paper
• [Unique type of Cushing's disease in clinical profile: cyclic Cushing's syndrome and Cushing's disease with favorable outcome to a high daily dose of bromocriptine].

  1994cites this paper
• Pathogenesis of pituitary Cushing's syndrome. Pituitary versus hypothalamic.

  1994cites this paper
• Bcl-2 gene prevents apoptosis in murine acth-secreting adenoma cells induced by bromocriptine.

  1994cites this paper
• Induction of apoptosis in murine ACTH‐secreting pituitary adenoma cells by bromocriptine

  1994cites this paper
• The state of the renin-angiotensin-aldosterone system in patients with the neuroendocrine-metabolic form of the hypothalamic syndrome

  1993cites this paper
• The medical treatment of Cushing's syndrome.

  1993cites this paper
• Induction of apoptosis in rat somatotrophin-secreting pituitary adenoma cells by bromocriptine.

  1993cites this paper
• The cellular and molecular basis of the ectopic ACTH syndrome

  1993cites this paper
• High prolactin levels in patients with Cushing's disease without pathological evidence of pituitary adenoma

  1993cites this paper
• Effective long-term treatment of a suspected pituitary adenoma with bromocriptine mesylate in a pony

  1992cites this paper
• Bromocriptine inhibits pro-opiomelanocortin mRNA and ACTH precursor secretion in small cell lung cancer cell lines.

  1992cites this paper
• Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease.

  1992cites this paper
• The treatment of Cushing's syndrome

  1991cites this paper
• Cortisol-suppressible dexamethasone-nonsuppressible cyclic Cushing's disease with evidence of clinical and biochemical remission with bromocriptine.

  1991cites this paper
• Effect of dopamine, dopamine D-1 and D-2 receptor modulation on ACTH and cortisol levels in normal men and women.

  1990cites this paper
• THE EFFECT OF CYPROHEPTADINE AND/OR BROMOCRIPTINE ON PLASMA ACTH LEVELS IN PATIENTS CURED OF CUSHING'S DISEASE BY BILATERAL ADRENALECTOMY

  1990cites this paper
• A case of Cushing's disease successfully treated with bromocriptine.

  1990cites this paper
• Cortisol secretion in patients with normoprolactinemic amenorrhea.

  1988cites this paper
• A BROMOCRIPTINE‐RESPONSIVE CORTICOTROPH ADENOMA SECRETING α‐MSH IN A PATIENT WITH CUSHING'S DISEASE

  1988cites this paper
• Pituitary adenomas in Cushing's disease: do they arise from the intermediate lobe?

  1988cites this paper
• Diseases of the adrenal cortex.

  1988cites this paper
• Factors involved in the regulation of adrenocorticotropic hormone/beta-lipotropic hormone.

  1988cites this paper
• Cushing's disease.

  1987cites this paper
• Pathogenesis of pituitary tumors.

  1987cites this paper
• Prolonged remission of Cushing's disease following bromocriptine therapy.

  1987cites this paper
• Depressive symptoms and the dexamethasone suppression test in parkinsonian patients.

  1987cites this paper
• RESPONSE TO NEUROTRANSMITTER MODULATING DRUGS IN PATIENTS WITH CUSHING'S DISEASE

  1986cites this paper
• The distribution of immunoreactive alpha-melanocyte-stimulating hormone cells in the adult human pituitary gland.

  1986cites this paper
• [Histological changes and operative findings of pituitary adenomas after bromocriptine treatment].

  1986cites this paper